MyOme Appoints Two Healthcare Leaders to Board as AI Genomics Platform Expands

Key Takeaways

• MyOme appointed Sam Roosz and Dr. Ravi Thadhani to its Board of Directors to strengthen leadership in AI-powered genomics
• The appointments bring expertise in healthcare technology, data portability, clinical trials, and regulatory strategy
• Strategic move positions MyOme for expansion of its whole-genome healthcare platform in competitive genomics market

---

MyOme, a genomics innovation and risk modeling company, announced April 21, 2026, the appointment of Sam Roosz and Dr. Ravi Thadhani to its Board of Directors, strengthening its leadership team as the company expands its AI-powered whole-genome healthcare platform.

The Menlo Park, California-based company selected both executives for their complementary expertise spanning healthcare technology, data portability, clinical trials, population health, and regulatory strategy—critical areas as MyOme scales its genomics solutions.

Strategic Leadership Enhancement

The board appointments come at a pivotal time for MyOme as the genomics industry experiences rapid growth driven by advances in artificial intelligence and personalized medicine. The company’s whole-genome healthcare platform leverages AI to provide risk modeling and genomic insights for healthcare providers and patients.

Sam Roosz brings extensive experience in healthcare technology and data systems, while Dr. Ravi Thadhani contributes deep clinical and regulatory expertise as an Executive Vice President with a background in population health initiatives.

Market Positioning and Growth Strategy

The leadership expansion reflects MyOme’s commitment to strengthening its competitive position in the genomics market, where companies are increasingly integrating AI capabilities with genetic analysis. The appointments signal the company’s preparation for potential expansion phases and regulatory navigation as genomics solutions become more mainstream in clinical practice.

The genomics industry has seen increased investment and adoption as healthcare systems seek personalized treatment approaches. MyOme’s focus on AI-powered risk modeling positions it within the growing intersection of artificial intelligence and precision medicine.

Industry Impact

These strategic appointments demonstrate MyOme’s focus on building leadership depth across key operational areas. The combination of technology expertise and clinical knowledge represented by the new board members aligns with industry trends toward comprehensive genomics platforms that can navigate both technical innovation and healthcare regulatory requirements.

---

Frequently Asked Questions

What expertise do the new MyOme board members bring?

Sam Roosz brings healthcare technology and data portability expertise, while Dr. Ravi Thadhani contributes clinical trials, population health, and regulatory strategy experience.

How will these appointments impact MyOme’s AI genomics platform?

The appointments strengthen MyOme’s leadership in key areas needed for platform expansion, including regulatory navigation, clinical applications, and healthcare technology integration.

What is MyOme’s main focus in the genomics market?

MyOme focuses on AI-powered whole-genome healthcare platforms that provide risk modeling and genomic insights for healthcare providers and patients.